新五豐(600975.SH):擬與耒陽新融共設新合農牧 開展生豬育肥養殖業務
格隆匯 12 月 8日丨新五豐(600975.SH)公佈,為推動生豬育肥事業發展,帶動當地農村經濟,新五豐擬與耒陽新融共同投資設立新合農牧。新合農牧註冊資金3000萬元,其中:新五豐以貨幣方式出資2400萬元,佔股份總數80%,耒陽新融以貨幣方式出資600萬元,佔股份總數20%。
此次設立完成後,新合農牧將採取合作育肥模式,開展生豬育肥養殖業務。該項目的建設投資主要包括首批投資仔豬15000頭費用,首批生豬飼料成本,前期工作費用與預備費,首批生豬養殖期間公司員工工資與管理、銷售費用,醫藥費用與環保處理費用,流動資金預估投資費用,第一年的利息費用,項目總投資合計5986.85萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.